Every Form 4 that Maze Therapeutics, Inc. (MAZE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, reported an option exercise and related share sale. On January 7, 2026, he exercised a stock option for 25,156 shares of common stock at an exercise price of $10.42 per share, converting a previously held derivative position into common stock.
On the same day, he sold the same 25,156 shares of common stock at a weighted average price of $40.2011 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025, leaving him with 0 directly held common shares and 312,407 stock options outstanding. The sale price reflects multiple transactions between $40.00 and $40.55 per share.
Maze Therapeutics director Catherine A. Sohn reported a series of stock option exercises and related common share sales. On January 6, 2026, she exercised 2,493 stock options at an exercise price of $10.42 per share and sold 2,493 common shares at a weighted average price of $38.616 per share, leaving no common shares directly owned.
On January 7, 2026, she exercised additional options for 20,744, 2,895, and 3,281 common shares at an exercise price of $10.42 per share and then sold 26,920 common shares at a weighted average price of $39.1079 per share, again ending with 0 common shares directly held. Following these transactions, she continues to hold stock options, including 3,211, 316, and 5,805 derivative securities with expiration dates between 2031 and 2034.
Maze Therapeutics, Inc. officer Harold Bernstein reported option exercises and share sales. On January 2, 2026, he exercised stock options to acquire 4,432 shares of common stock at $10.42 per share and sold 4,432 shares of common stock at a weighted average price of $40.4304 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. On January 5, 2026, he exercised options to acquire an additional 412 shares at $10.42 and sold 412 shares at $40.00 per share. Following these transactions, he continued to hold stock options, including 337,563 option shares directly owned, which vest over time according to a set schedule.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and share sales in company stock. On January 2, 2026, she exercised stock options for 204 and 4,796 shares of common stock at an exercise price of $10.42 per share. These options relate to grants that vest monthly and one award that was fully vested as of March 1, 2025.
On the same date, she sold 2,405 shares at a weighted average price of $38.6995 and 2,595 shares at a weighted average price of $39.5689, in multiple trades within stated price ranges. After these transactions, she directly held 12,965 shares of common stock and 2,377 and 2,983 stock options. All trades were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Maze Therapeutics, Inc. director reports receipt of common stock through fund distribution. A Maze Therapeutics, Inc. (MAZE) director reported acquiring 1,489 shares of common stock on 11/19/2025 at a price of $0 per share, described as his pro rata share of a distribution from entities affiliated with Third Rock Ventures made for no consideration under an Exchange Act exemption. Following this transaction, he beneficially owns 31,113 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, for which he serves as trustee. This is a routine ownership reporting update rather than a new open-market purchase or sale.
Maze Therapeutics (MAZE): Form 4 insider activity
Affiliates of Third Rock Ventures reported a pro rata, for-no-consideration distribution of 1,600,000 shares of Maze Therapeutics common stock on November 4, 2025, noted with transaction code J and described as exempt under Rules 16a-13 and 16a-9. Following the distribution, the filing shows 4,473,958 shares beneficially owned directly and 950,800 shares beneficially owned indirectly, with relationships indicated including director and 10% owner statuses and standard beneficial ownership disclaimers among the TRV entities.
Maze Therapeutics (MAZE) reported an insider transaction by a director. On 10/23/2025, the reporting person made a gift of 28,423 shares of common stock, recorded at $0 as a no‑consideration transfer exempt under Rule 16b‑5.
Following the transaction, the filer beneficially owned 29,624 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is trustee.
Maze Therapeutics, Inc. director Herve Hoppenot was granted a stock option on 10/06/2025 to buy 36,000 shares of common stock at an exercise price of $27.52 per share. The option vests monthly at 1/36 of the award beginning on 11/06/2025 and on each monthly anniversary thereafter, subject to continued service, and expires on 10/05/203536,000 options directly. The filing was signed by an attorney-in-fact on 10/07/2025.
Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, acquired 22,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement, and the award shows 22,000 shares beneficially owned after the grant at a reported price of $0. The RSUs vest 50% on 09/01/2026 and 50% on 09/01/2027, contingent on continued service, and the units do not expire; they vest or are cancelled prior to vesting dates.
Maze Therapeutics insider award: Atul Dandekar, listed as CSBO and officer, was granted 25,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of Maze Therapeutics common stock upon settlement. The award vests in two equal installments: 12,500 RSUs on September 1, 2026 and 12,500 RSUs on September 1, 2027, subject to the reporting persons continued service on each vesting date. The RSUs do not expire and will either vest or be cancelled prior to the vesting dates. After the grant, the reporting person beneficially owns 25,000 shares (directly) from this award. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics (MAZE), was granted 100,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement and the grant carries a $0 per-share price. The award vests in two equal installments: 50,000 RSUs on September 1, 2026 and 50,000 RSUs on September 1, 2027, contingent on continued service. The RSUs do not have an expiration date and will be cancelled if unvested prior to vesting.
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported the grant of 40,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of common stock upon settlement. The award vests in two equal installments: 20,000 RSUs vest on September 1, 2026 and 20,000 RSUs vest on September 1, 2027, subject to continued service. The RSUs have no exercise price and do not expire; they either vest or are cancelled prior to vesting. The reported ownership following the grant is 40,000 shares held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Amy Bachrodt, SVP Finance of Maze Therapeutics (MAZE), was granted 22,000 restricted stock units on 09/22/2025. Each unit converts to one share of common stock upon settlement and the reporting person beneficially owns 22,000 shares after the reported transaction.
The award vests in two equal installments: 11,000 RSUs on September 1, 2026 and 11,000 RSUs on September 1, 2027, contingent on continued service. The RSUs have no expiration; they either vest or are cancelled before vesting. The Form 4 was executed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Daniel K. Spiegelman received a stock option award on 09/22/2025. The Form 4 shows an option to buy 18,000 shares of Maze common stock at an exercise price of $23.67 per share. The option was reported as acquired on 09/22/2025 and is recorded as directly beneficially owned with 18,000 shares following the transaction. The option has an expiration/exercise date shown as 09/21/2035 and vests monthly in nine equal tranches (1/9 each) beginning with a first tranche vesting on October 1, 2025, subject to continued service. The filing was signed by an attorney-in-fact on 09/24/2025.
Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.
The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.
Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.
Maze Therapeutics director Charles J. Homcy was granted a stock option to buy 18,000 shares of Maze Therapeutics common stock at an exercise price of $23.67 per share. The option is reported as a direct holding and covers 18,000 underlying shares with an exercise/expiration reference shown as 09/21/2035. The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to the holder’s continued service.
The grant increases the reporting person’s beneficial ownership by 18,000 shares on the reported transaction date of September 22, 2025. No cash exercise is indicated in the filing and the option is described as a right to buy common stock under standard vesting conditions tied to continued service.
Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share. The option was granted on 09/22/2025, is exercisable beginning 09/21/2025, and expires 09/21/2035. The award vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.
Maze Therapeutics director Nancy C. Andrews was granted a stock option on 09/22/2025 to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) common stock at an exercise price of $23.67 per share. The option award appears in a Form 4 filed on 09/24/2025 and is reported as a direct beneficial holding of 18,000 underlying shares after the transaction. The disclosure states the option will vest in nine equal monthly tranches (1/9 each month) with the first tranche vesting on October 1, 2025, subject to continued service. The instrument lists a date of exercisability/expiration of 09/21/2035 and zero listed cash paid on exercise in the table.